和铂医药(02142.HK)HBM7004治疗晚期实体瘤新药临床获批

阿斯达克财经
Aug 18

和铂医药(02142.HK) 公布,HBM7004(一款治疗晚期实体瘤的新型B7H4xCD3双特异性抗体)的新药临床试验申请已获国家药监局批准。是继集团获美国食品药品监督管理局许可其IND申请于美国启动首次人体I期临床试验后取得的又一进展。(ha/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-18 16:25。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10